CAS: 761423-87-4; (2S,3R,4R,5S,6R)-2-(3-(Benzo[b]Thiophen-2-Ylmethyl)-4-Fluorophenyl)-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-Triol

上下游产品

CAS号1034305-21-9 (1S)-1,5-脱水-1-C... | CAS号1034305-11-7 苯并[B]噻吩-2-基(5-溴... | CAS号1034305-17-3 2-(5-溴-2-氟苄基)苯并噻吩 | CAS号93777-26-5 5-溴-2-氟苯甲醛 | CAS号95-15-8 苯并噻吩

在 三乙基硅烷,Boron Trichloride Acetic Acid体系中,用 二氯甲烷,乙腈 作为反应溶剂,以70.2%的收率获得产物ipragliflozin; (1S)-1,5-脱水-1-C-[3-[(1-苯并噻吩-2-基)甲基]-4-氟苯基]-D-葡糖醇
参考文献:一种sglt-2抑制剂化合物的制备方法
标题:一种sglt-2抑制剂化合物的制备方法
摘要:本发明涉及一种sglt-2抑制剂化合物的制备方法,利用化合物a通过羟基保护,偶联反应,羟基脱保护,缩酮反应步骤得到中间体ⅰ,再通过得到的中间体ⅰ制备sglt-2抑制剂化合物.

专利信息

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人：SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:EP-2918579-A1
优先权日:2014-03-14
标题 :Synthesis of 2-arylmethyl-5-aryl-thiophene
权利人:LEK PHARMACEUTICALS
摘要:The present invention provides a new synthetic process for the production of 2-arylmethyl-5-aryl-thiophene, an intermediate in the synthesis of C-aryl glycosides.

专利号:US-2018370905-A1
优先权日:2013-04-05
标题:Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same

专利号:US-10906888-B2
优先权日:2016-07-14
标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
发明人：CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9018249-B2
优先权日:2011-09-13
标题 :SGLT inhibitors
发明人：JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR
权利人:JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR; PANACEA BIOTEC LTD
摘要:The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

专利号:US-2014228303-A1
优先权日:2011-06-13
标题 :Novel sglt inhibitors
发明人：JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR
权利人:JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR; PANACEA BIOTEC LTD
摘要:The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).